The UK Medicines and Healthcare products Regulatory Agency (MHRA) has revoked a conditional marketing authorisation for Novartis Pharmaceuticals’ Adakveo 10mg/ml concentrate for solution for infusion to treat sickle cell disease.

The decision was made after the Phase III STAND study failed to validate the clinical benefit of Adakveo in treating patients who have vaso-occlusive crises.

Novartis is recalling the product as the MHRA no longer deems its benefit-risk balance favourable.

Healthcare professionals were instructed by the regulator to immediately stop the supply of the affected batch and quarantine remaining stock.

Novartis, which has a direct-to-pharmacy supply chain agreement, is aware of the hospitals that received the impacted batch.

The company’s customer care team arrange the return of the product.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Clinicians and prescribers are advised to inform patients currently on Adakveo about the licence revocation and discuss alternative therapies.

The MHRA advised healthcare professionals to not begin treatment with Adakveo in new patients.

Patients who are prescribed Adakveo should not stop the treatment without consulting their healthcare professional.

In case of adverse reactions or queries about the medication, patients should seek medical attention.

The MHRA encouraged reporting of any suspected adverse reactions through the Yellow Card scheme.

A Dear Healthcare Professional Letter has been issued by Novartis to announce the revocation.

The latest development comes after the human medicines committee of the European Medicines Agency recommended revoking the marketing authorisation for Adakveo in sickle cell disease patients aged 16 years and above last year.